{"title":"新疗法的未来是怎样的","authors":"K. Bork","doi":"10.1016/j.allerg.2008.01.012","DOIUrl":null,"url":null,"abstract":"<div><p>A certain number of new potential therapies for hereditary angioedema (HAE) are currently being studied. They include new inhibitors of the contact system, such as ecallantide, a kallikrein inhibitor, Icatibant, a bradykinin receptor B2 antagonist, as well as a recombinant C1-INH secreted in the milk of transgenic rabbits. Publication of the data concerning these state-of-the-art therapies could be the beginning of new therapeutic advances in the treatment of HAE and, hopefully, lead to reduction in the burden that this condition represents.</p></div>","PeriodicalId":92953,"journal":{"name":"Revue francaise d'allergologie et d'immunologie clinique","volume":"48 3","pages":"Pages 159-161"},"PeriodicalIF":0.0000,"publicationDate":"2008-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.allerg.2008.01.012","citationCount":"0","resultStr":"{\"title\":\"Quel avenir pour les nouvelles thérapeutiques ?\",\"authors\":\"K. Bork\",\"doi\":\"10.1016/j.allerg.2008.01.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A certain number of new potential therapies for hereditary angioedema (HAE) are currently being studied. They include new inhibitors of the contact system, such as ecallantide, a kallikrein inhibitor, Icatibant, a bradykinin receptor B2 antagonist, as well as a recombinant C1-INH secreted in the milk of transgenic rabbits. Publication of the data concerning these state-of-the-art therapies could be the beginning of new therapeutic advances in the treatment of HAE and, hopefully, lead to reduction in the burden that this condition represents.</p></div>\",\"PeriodicalId\":92953,\"journal\":{\"name\":\"Revue francaise d'allergologie et d'immunologie clinique\",\"volume\":\"48 3\",\"pages\":\"Pages 159-161\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.allerg.2008.01.012\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue francaise d'allergologie et d'immunologie clinique\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0335745708000373\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue francaise d'allergologie et d'immunologie clinique","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0335745708000373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A certain number of new potential therapies for hereditary angioedema (HAE) are currently being studied. They include new inhibitors of the contact system, such as ecallantide, a kallikrein inhibitor, Icatibant, a bradykinin receptor B2 antagonist, as well as a recombinant C1-INH secreted in the milk of transgenic rabbits. Publication of the data concerning these state-of-the-art therapies could be the beginning of new therapeutic advances in the treatment of HAE and, hopefully, lead to reduction in the burden that this condition represents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
